MedTrace Logo

Financial Incentives for Smoking Treatment

NCT02506829 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2020-12-11

No results posted yet for this study

Summary

The investigators plan to compare the impact of two approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life among a diverse population of patients at the Manhattan campus of the VA New York Harbor Healthcare System, which serves a critical safety-net role for urban veterans. During hospitalization, all smokers will receive usual care. Patients will be randomized to one of two arms: financial incentives plus usual care vs. usual care alone, which includes referral to the state Quitline. All patients enrolled in the study will be offered nicotine replacement therapy. The investigators will conduct follow-up assessments at 2 weeks, 2 months, 6 months and 12 months after discharge. The primary study outcome is smoking abstinence at 6-month follow-up, verified by salivary/urinary cotinine.

Conditions

  • Smoking
  • Smoking, Tobacco
  • Tobacco Use Disorder

Interventions

BEHAVIORAL

Smoking cessation counseling (Quitline)

BEHAVIORAL

Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)

BEHAVIORAL

Financial incentives

Sponsors & Collaborators

Principal Investigators

  • Joseph Ladapo, MD, PhD · University of California, Los Angeles

  • Scott Sherman, MD, MPH · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-03-05
Completion
2019-05-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02506829 on ClinicalTrials.gov